Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,130.00
(
0.48%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
99.49
(
-1.16%
)
Bitcoin
74,612.70
(
0.91%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

zipjet

Send PM Follow Ignore
Followers 36
Posts 2637
Boards Moderated 0
Alias Born 10/06/2003

zipjet

Re: DewDiligence post# 101952

Thursday, 08/19/2010 7:23:04 PM

Thursday, August 19, 2010 7:23:04 PM

Post# of 257253

Robyn Karnauskas of Deutsche Bank forecasts that US Tysabri sales will fall from $633M in 2010 to $376M in 2015 as newer and safer MS drugs reach the market.



I'm all in for safer, IF EFFECTIVE, MS treatments. (My wife is on Tysabri after failing Copaxone.)

BUT what I am hearing is that Gilenia carries a cancer risk. Weighing a quantifiable PML risk against an unquantifiable cancer risk versus the ravages of MS is awful.

ij

There are times when rules and precedents cannot be broken; others when they cannot be adhered to with safety. (Thomas Joplin)

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now